Home » Topics » Articles » Insight

Insight
RSS

Are Investors Ready

Sep. 21, 1998

Clinical Trial Update: August 1998

Sep. 21, 1998

Financial Placements By Public Canadian Biotechnology Companies: January - August 1998

Sep. 14, 1998

Capital Investments In Selected Private Canadian Biotechnology Companies: January - July 1998

Sep. 14, 1998

Venture Funding Keeps Canadian Biotechnology Industry On A Roll

Sep. 14, 1998

By Peter Winter

German Biotech Boom Attracts U.S. Investors

Sep. 7, 1998

Money Raised By Biotech In 1998: January - August

Sep. 7, 1998

Public Financing Of Biotechnology: August 1998

Sep. 7, 1998

Other Financings Of Public Biotechnology Companies: August 1998

Sep. 7, 1998

Venture Capital, PIPE/Reg. S And Corporate Investments In Biotechnology Companies: August 1998

Sep. 7, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
Roche reports new TREM2 agonists
BioWorld Science
F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....
Recludix’s first-in-class STAT6 inhibitor shows efficacy in atopic dermatitis
BioWorld Science
Researchers from Recludix Pharma Inc. reported preclinical efficacy data on REX-8756 (SAR-448755), a first-in-class orthosteric STAT6 inhibitor in models of...